Arrowhead Pharmaceuticals, Inc.
ARWRHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Arrowhead Pharmaceuticals, Inc. (ARWR) is listed under Biotechnology. With a market capitalization of $8.22B, it sits in mid-cap territory. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials.
Market Cap
$8.22B
Beta
1.30
P/E (TTM)
—
P/E (Fwd)
-11.72
EPS (TTM)
$-2.26
EPS (Fwd)
$-4.98
ROE
-55.2%
ROA
-8.1%
Cash
$1.60B
Total Debt
$1.38B
Free CF
-$48.6M
52W Change
56.3%
Annual Financials
Cash vs Debt
Where ARWR stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, ARWR finished 23.26% below its 150-day moving average ($74.58) and 20.56% below its 200-day moving average ($72.04). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ARWR overbought or oversold?
At the October 20, 2026 close, ARWR's RSI(14) was 22.6, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $1.60B in cash comfortably exceeding the $1.38B debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$48.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -55.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $243.2M to $829.4M.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Arrowhead Pharmaceuticals, Inc.'s trajectory.